(Q27002539)

28 October 2020

anti-inflammatory agent

1 reference

19 July 2021

1

Alfonso E. Bello

1 reference

Robert J. Holt

2

1 reference

language of work or name

1 reference

November 2014

1 reference

1 November 2014

3 references

17 June 2019

28 October 2020

19 July 2021

4 references

17 June 2019

28 October 2020

19 July 2021

37

1 reference

page(s)

897-902

1 reference

issue

11

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

copyright license

1 reference

Europe PubMed Central

https://scigraph.springernature.com/pub.10.1007/s40264-014-0207-2

19 July 2021

exact match

0 references

cites work

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

21 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Interaction revisited: the difference between two estimates

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

The impact of NSAID treatment on cardiovascular risk - insight from Danish observational data

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Guidelines for prevention of NSAID-related ulcer complications

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206767

Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

28 September 2017

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0207-2

Expression of concern reaffirmed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0207-2

Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-014-0207-2

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/25079141

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25079141

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40264-014-0207-2

0 references

Dimensions Publication ID

1051399609

0 references

Fatcat ID

release_fnjwrvtjojbw5dh6rbaezuvyhe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fnjwrvtjojbw5dh6rbaezuvyhe